217 related articles for article (PubMed ID: 31345011)
41. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
[TBL] [Abstract][Full Text] [Related]
42. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
43. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
44. Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.
Wang J; Li X; Xue X; Ou Q; Wu X; Liang Y; Wang X; You M; Shao YW; Zhang Z; Zhang S
Int J Cancer; 2019 Jun; 144(11):2677-2682. PubMed ID: 30255937
[TBL] [Abstract][Full Text] [Related]
45. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
[TBL] [Abstract][Full Text] [Related]
46. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
Nützinger J; Bum Lee J; Li Low J; Ling Chia P; Talisa Wijaya S; Chul Cho B; Min Lim S; Soo RA
Lung Cancer; 2023 Dec; 186():107385. PubMed ID: 37813015
[TBL] [Abstract][Full Text] [Related]
47. Targeting HER2 in the treatment of non-small cell lung cancer.
Mar N; Vredenburgh JJ; Wasser JS
Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
[TBL] [Abstract][Full Text] [Related]
48. HER2 and lung cancer.
Landi L; Cappuzzo F
Expert Rev Anticancer Ther; 2013 Oct; 13(10):1219-28. PubMed ID: 24134423
[TBL] [Abstract][Full Text] [Related]
49. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
50. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital.
Choi YL; Sun JM; Cho J; Rampal S; Han J; Parasuraman B; Guallar E; Lee G; Lee J; Shim YM
PLoS One; 2013; 8(2):e56011. PubMed ID: 23468851
[TBL] [Abstract][Full Text] [Related]
51. Proportion and clinical features of never-smokers with non-small cell lung cancer.
Cho J; Choi SM; Lee J; Lee CH; Lee SM; Kim DW; Yim JJ; Kim YT; Yoo CG; Kim YW; Han SK; Park YS
Chin J Cancer; 2017 Feb; 36(1):20. PubMed ID: 28179026
[TBL] [Abstract][Full Text] [Related]
52. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
53. HER2 mutations in Chinese patients with non-small cell lung cancer.
Song Z; Yu X; Shi Z; Zhao J; Zhang Y
Oncotarget; 2016 Nov; 7(47):78152-78158. PubMed ID: 27825109
[TBL] [Abstract][Full Text] [Related]
54. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
55. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
Suzawa K; Toyooka S; Sakaguchi M; Morita M; Yamamoto H; Tomida S; Ohtsuka T; Watanabe M; Hashida S; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S
Cancer Sci; 2016 Jan; 107(1):45-52. PubMed ID: 26545934
[TBL] [Abstract][Full Text] [Related]
56. Non-amplification genetic alterations of
Mehta A; Nathany S; Tripathi R; Sharma SK; Saifi M; Batra U
J Clin Pathol; 2021 Feb; 74(2):106-110. PubMed ID: 32527755
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.
Baek JH; Sun JM; Min YJ; Cho EK; Cho BC; Kim JH; Ahn MJ; Park K
Lung Cancer; 2015 Feb; 87(2):148-54. PubMed ID: 25498243
[TBL] [Abstract][Full Text] [Related]
58. The force of HER2 - A druggable target in NSCLC?
Jebbink M; de Langen AJ; Boelens MC; Monkhorst K; Smit EF
Cancer Treat Rev; 2020 Jun; 86():101996. PubMed ID: 32135383
[TBL] [Abstract][Full Text] [Related]
59. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
60. Consensus for HER2 alterations testing in non-small-cell lung cancer.
Ren S; Wang J; Ying J; Mitsudomi T; Lee DH; Wang Z; Chu Q; Mack PC; Cheng Y; Duan J; Fan Y; Han B; Hui Z; Liu A; Liu J; Lu Y; Ma Z; Shi M; Shu Y; Song Q; Song X; Song Y; Wang C; Wang X; Wang Z; Xu Y; Yao Y; Zhang L; Zhao M; Zhu B; Zhang J; Zhou C; Hirsch FR
ESMO Open; 2022 Feb; 7(1):100395. PubMed ID: 35149428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]